ZA200401181B - Novel combination - Google Patents
Novel combination Download PDFInfo
- Publication number
- ZA200401181B ZA200401181B ZA2004/01181A ZA200401181A ZA200401181B ZA 200401181 B ZA200401181 B ZA 200401181B ZA 2004/01181 A ZA2004/01181 A ZA 2004/01181A ZA 200401181 A ZA200401181 A ZA 200401181A ZA 200401181 B ZA200401181 B ZA 200401181B
- Authority
- ZA
- South Africa
- Prior art keywords
- carbon atoms
- straight
- chain
- alkyl
- radical
- Prior art date
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims description 113
- -1 alcoholates Chemical class 0.000 claims description 71
- 239000004480 active ingredient Substances 0.000 claims description 40
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 150000003254 radicals Chemical class 0.000 claims description 35
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical class 0.000 claims description 31
- 125000002252 acyl group Chemical class 0.000 claims description 29
- 125000003545 alkoxy group Chemical class 0.000 claims description 29
- 125000004453 alkoxycarbonyl group Chemical class 0.000 claims description 27
- 239000013066 combination product Substances 0.000 claims description 27
- 229940127555 combination product Drugs 0.000 claims description 27
- 125000005842 heteroatom Chemical group 0.000 claims description 27
- 239000003524 antilipemic agent Substances 0.000 claims description 26
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 229920006395 saturated elastomer Polymers 0.000 claims description 23
- 150000001875 compounds Chemical class 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 claims description 16
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 claims description 14
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 239000001257 hydrogen Substances 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 claims description 13
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical group CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims description 10
- 125000004414 alkyl thio group Chemical class 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- 125000004442 acylamino group Chemical group 0.000 claims description 8
- 229960005110 cerivastatin Drugs 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 8
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims description 7
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 6
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 229960005370 atorvastatin Drugs 0.000 claims description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003119 guanylate cyclase activator Substances 0.000 claims description 5
- 150000004677 hydrates Chemical class 0.000 claims description 5
- 229960002797 pitavastatin Drugs 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000001425 triazolyl group Chemical group 0.000 claims description 5
- KQTGCJMBUBYSLL-UHFFFAOYSA-N 4-piperidin-1-ylmorpholine Chemical compound C1CCCCN1N1CCOCC1 KQTGCJMBUBYSLL-UHFFFAOYSA-N 0.000 claims description 4
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 4
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 4
- 239000003613 bile acid Substances 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229960003765 fluvastatin Drugs 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 4
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 claims description 4
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 4
- 229960002965 pravastatin Drugs 0.000 claims description 4
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 4
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 4
- 229960000672 rosuvastatin Drugs 0.000 claims description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 4
- 125000005505 thiomorpholino group Chemical group 0.000 claims description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 3
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 229920000080 bile acid sequestrant Polymers 0.000 claims description 3
- 229940096699 bile acid sequestrants Drugs 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 229960004844 lovastatin Drugs 0.000 claims description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 3
- 229960002855 simvastatin Drugs 0.000 claims description 3
- 150000001204 N-oxides Chemical class 0.000 claims description 2
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical group [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003003 spiro group Chemical group 0.000 claims description 2
- 239000004059 squalene synthase inhibitor Substances 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 34
- 230000000694 effects Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 159000000007 calcium salts Chemical class 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 150000003278 haem Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 108010078321 Guanylate Cyclase Proteins 0.000 description 3
- 102000014469 Guanylate cyclase Human genes 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- YURNCBVQZBJDAJ-AATRIKPKSA-N (E)-hept-2-enoic acid Chemical compound CCCC\C=C\C(O)=O YURNCBVQZBJDAJ-AATRIKPKSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 229920002911 Colestipol Polymers 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 229960003526 acipimox Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 2
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 2
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JVVXZOOGOGPDRZ-UHFFFAOYSA-N (1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl)methanamine Chemical compound NCC1(C)CCCC2(C)C3=CC=C(C(C)C)C=C3CCC21 JVVXZOOGOGPDRZ-UHFFFAOYSA-N 0.000 description 1
- FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 description 1
- VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical class C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- OGIYDFVHFQEFKQ-UHFFFAOYSA-N 3-[n-(4,5-dihydro-1h-imidazol-2-ylmethyl)-4-methylanilino]phenol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 OGIYDFVHFQEFKQ-UHFFFAOYSA-N 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- VXDSGTRNDFHIJB-QQPOVDNESA-N [(1s,4ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006251 butylcarbonyl group Chemical group 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229940097479 colestid Drugs 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940066901 crestor Drugs 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
- 229950003040 dalvastatin Drugs 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VXDSGTRNDFHIJB-UHFFFAOYSA-N dihydrocompactin Natural products C12C(OC(=O)C(C)CC)CCCC2C=CC(C)C1CCC1CC(O)CC(=O)O1 VXDSGTRNDFHIJB-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- XRKMNJXYOFSTBE-UHFFFAOYSA-N disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate Chemical compound O.O.[Na+].[Na+].[Fe+4].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].O=[N-] XRKMNJXYOFSTBE-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000006328 iso-butylcarbonyl group Chemical group [H]C([H])([H])C([H])(C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- 235000008718 isoliquiritigenin Nutrition 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 229940095570 lescol Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 229940063720 lopid Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- GACQNVJDWUAPFY-UHFFFAOYSA-N n'-[2-[2-(2-aminoethylamino)ethylamino]ethyl]ethane-1,2-diamine;hydrochloride Chemical compound Cl.NCCNCCNCCNCCN GACQNVJDWUAPFY-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004673 propylcarbonyl group Chemical group 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000005229 pyrazolopyridines Chemical class 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229940072168 zocor Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Description
Novel combination
The present invention relates to a novel combination product comprising at least one lipid-lowering agent and at least one compound able to stimulate soluble guanylate cyclase.
One of the most important cellular transmission systems in mammalian cells is cyclic guanosine monophosphate (cGMP). Together with nitric oxide (NO), which is released from the endothelium and transmits hormonal and mechanical signals, it forms the NO/cGMP system. Guanylate cyclases catalyze the biosynthesis of cGMP from guanosine triposphate (GTP). The representatives of this family disclosed to date can be divided both according to structural features and according to the type of ligands into two groups: the particulate guanylate cyclases which can be stimulated by natriuretic peptides, and the soluble guanylate cyclases which can be stimulated by
NO. The soluble guanylate cyclases consist of two subunits and very probably contain one heme per heterodimer, which is part of the regulatory site. The latter is of central importance for the mechanism of activation. NO is able to bind to the iron atom of heme and thus markedly increase the activity of the enzyme. CO is also able to attach to the central iron atom of heme, but the stimulation by CO is distinctly less than that by NO.
Through the production of cGMP and the regulation, resulting therefrom, of phosphodiesterases, ion channels and protein kinases, guanylate cyclase plays a crucial part in various physiological processes, in particular in the relaxation and proliferation of smooth muscle cells, in platelet aggregation and adhesion and in neuronal signal transmission, and in disorders caused by an impairment of the aforementioned processes.
Compounds, such as organic nitrates, whose effect is based on the release of NO have to date been exclusively used for the therapeutic stimulation of soluble guanylate cyclase. NO is produced by bioconversion and activates soluble guanylate cyclase by attaching to the central iron atom of heme. Besides the side effects, the development of tolerance is one of the crucial disadvantages of this mode of treatment.
Some substances which directly stimulate soluble guanylate cyclase, i.e. without previous release of NO, have been described in recent years, such as, for example, 3-(5¢-hydroxymethyl-2*-furyl)-1-benzylindazole (YC-1, Wu et al., Blood 84 (1994), 4226; Miilsch et al., Br. J. Pharmacol. 120 (1997), 681), fatty acids (Goldberg et al, - J. Biol. Chem. 252 (1977), 1279), diphenyliodonium hexafluorophosphate (Pettibone et al, Eur. J. Pharmacol. 116 (1985), 307), isoliquiritigenin (Yu et al., Brit.
J. Pharmacol. 114 (1995), 1587) and various substituted pyrazole derivatives (WO 98/16223).
In addition, WO 98/16507, WO 98/23619, WO 00/06567, WO 00/06568,
WO 00/06569 and WO 00/21954 describe pyrazolopyridine derivatives as stimulators of soluble guanylate cyclase.
It has now been found, surprisingly, that the effect of the direct soluble guanylate cyclase stimulators described above can be enhanced on administration of a lipid- lowering agent in combination with these soluble guanylate cyclase stimulators.
The present invention further relates to the use of lipid-lowering agents for enhancing the effect of direct soluble guanylate cyclase stimulators in the treatment of diseases which can be influenced by stimulation of soluble guanylate cyclase.
It is possible in this way for example to reduce the amount of direct soluble guanylate cyclase stimulator, or amount of lipid-lowering agent, which are necessary for the treatment of diseases and thus diminish the potential for side effects.
The present invention thus relates to a combination product comprising e as active ingredient component A at least one direct soluble guanylate cyclase stimulator; and e as active ingredient component B at least one lipid-lowering agent.
The term “combination product” as used for the purposes of the present invention means that the two active ingredient components A and B can be administered either simultaneously or sequentially (i.e. separately from one another).
The term “combination product” thus encompasses, according to the invention, ingredients A and B either in one functional unit, i.e. as true combination (e.g. as mixture, mix or blend), or else (spatially) separate in juxtaposition, i.e. as so-called kit of parts.
The present invention thus further relates also to a combination therapy for diseases which can be influenced by stimulation of soluble guanylate cyclase using a combination product which comprises at least one direct soluble guanylate cyclase stimulator and at least one lipid-lowering agent.
As mentioned previously, the combination of the invention can be administered, i.e. the combination therapy of the invention can take place, in such a way that the active ingredient components A and B are administered simultaneously. It is possible in this case for the active ingredient components A and B, as described above, to be present either in one functional unit (i.e. as true combination such as, for example, as mixture, mix or blend) or else (spatially) separate in juxtaposition (i.e. as so-called kit or kit-of-parts).
In a preferred embodiment of the present invention, the active ingredient components
A and B are administered separately from one another, in particular sequentially.
This can take place for example by administering a daily dose of the lipid-lowering agent some days (e.g. about 1 week or else only 1-4 days) before administration of the direct soluble guanylate cyclase stimulator.
It is also possible to administer the direct soluble guanylate cyclase stimulator within a pre-existing lipid-lowering agent therapy, for example for patients with severe hypercholesterolemia, in whom the elevated cholesterol levels are already treated permanently with lipid-lowering agents. In this case, therefore, administration of the lipid-lowering agent can also be continued before and in parallel with the administration of the direct soluble guanylate cyclase stimulator.
In a preferred embodiment of the present invention, the active ingredient components
A and B of the combination product of the invention are thus administered sequentially, preferably the lipid-lowering agent preceding, i.e. prior to, administration of the direct soluble guanylate cyclase stimulator.
Without wishing in this connection to be bound to a particular theory, the improvement in the effect of the direct soluble guanylate cyclase stimulator through simultaneous, sequential or parallel administration of lipid-lowering agents can presumably be explained by the fact that the lipid-lowering agents improve the impaired endothelial function by generating nitric oxide (NO) (Current Opinion in
Lipidology, 1997, Vol. 8, pages 362-368 and Circulation 1998, 97, pages 1129- 1135). It has been possible to show that direct soluble guanylate cyclase stimulators show a synergistic effect in combination with NO (cf., for example, WO 00/06569,
Fig. 1).
According to the present invention, the lipid-lowering agent can be selected from the group of: eo HMG-CoA reductase inhibitors, e squalene synthase inhibitors,
¢ bile acid absorption inhibitors (also called bile acid anion exchangers or bile acid sequestrants), e fibric acid and its denivatives, e nicotinic acid and its analogs and eo ®3-fatty acids.
For further details of the aforementioned lipid-lowering agents, reference is made in this connection to the article by Gilbert R. Thompson & Rissitaza P. Naoumova “New prospects for lipid-lowering drugs” in Exp. Opin. Invest. Drugs (1998), 7(5), pages 715 — 727, the entire contents of which are hereby expressly incorporated by reference.
The lipid-lowering agents preferred according to the invention amongst those aforementioned are the HMG-CoA reductase inhibitors. The abbreviation “HMG-
CoA” in this connection stands for “3-hydroxymethylglutaryl-coenzyme A”.
In turn, the HMG-CoA reductase inhibitors particularly preferred according to the invention belong to the substance class of vastatins - usually referred to only as “statins” for simplicity in the literature.
Those statins which are in turn particularly preferred according to the invention are e atorvastatin (commercially available under the name Lipitor® from Parke-Davis); e cerivastatin (commercially available under the name Lipobay® or Baycol® from
Bayer); ¢ fluvastatin (commercially available under the name Lescol® from Novartis); e lovastatin (commercially available under the name Mevacor® from Merck); e pravastatin (commercially available under the name Lipostat® from Bristol-
Myers Squibb); e simvastatin (commercially available under the name Zocor® from Merck);
e pitavastatin (also called “nisvastatin”; NK-104; systematic name: [S-[R*,S*- (E)]]-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-6- heptenoic acid); e dalvastatin; e mevastatin; ¢ dihydrocompactin; e compactin; and e rosuvastatin (commercially available under the name Crestor® from
AstraZeneca; systematic name: (+)-(3R,5S)bis(7-(4-(4-fluorophenyl)-6-isopropyl- 2-(N-methyl-N-methanesuifonylamino)pyrimidin-5-yl)-3,5-dihydroxy-6(E)- heptenoic acid); and the respective salts, hydrates, alcoholates, esters and tautomers thereof.
Very particularly preferred among these are atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, pitavastatin, simvastatin and rosuvastatin, and the respective salts, hydrates, alcoholates, esters and tautomers thereof.
Very particularly preferred among these in turn are cerivastatin and atorvastatin and the respective salts, hydrates, alcoholates, esters and tautomers thereof.
For further details of the aforementioned statins, reference 1s made to the discussiones in Drugs of the Future 1994, 19(6), pages 537 — 541 and 1995, 20(6), page 611 and 1996, 21(6), page 642, the contents of each of which are incorporated in their entirety by reference.
The term “salt” for the purposes of the present invention means in each case physiologically acceptable salts of the respective compounds. These may be, for example: salts of mineral acids, carboxylic acids or sulfonic acids, in particular with hydrochloric acid, hydrobromic acid or sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid or of mixed salts thereof.
However, salts with conventional bases are also possible, such as, for example, alkali metal salts (e.g. sodium or potassium salts), alkaline earth metal salts (e.g. calcium or magnesium salts) or ammonium salts derived from ammonia or organic amines such as, for example, diethylamine, triethylamine, ethyldiisopropylamine, procain, di- benzylamine, N-methylmorpholine, dihydroabietylamine, 1-ephenamine or methyl- piperidine and mixed salts thereof.
Examples of statin salts which can be used according to the invention are fluindostatin (the monosodium salt of fluvastatin); the monopotassium salt and the calcium salt of pitavastatin; and the calcium salt of (+)-(3R,5S)bis(7-(4-(4- fluorophenyl)-6-1sopropyl-2-(N-methyl-N-methanesulfonylamino)pyrimidin-5-yl)- 3,5-dihydroxy-6(E)-heptenoic acid (“rosuvastatin”, “ZD 4522” or “S 4522” from
Shionogi or AstraZeneca). Further examples of statin salts which can be used according to the invention are the monosodium and monopotassium salts, and the calcium salts of cerivastatin, of atorvastatin and of pravastatin.
Further preferred HMG-CoA reductase inhibitors are described in EP-A-0 325 130 and in EP-A-0-491 226, the contents of which are hereby incorporated by reference.
EP-A-0 325 130 relates to substituted pyridines, and EP-A-0-491 226 describes substituted pyridyldihydroxyheptenoic acid derivatives and their salts, particularly including cerivastatin which is particularly preferred according to the invention (claim 6 of EP-A-0-491 226).
Likewise preferred according to the invention are the statins mentioned in WO-A- 99/11263, the disclosure of which is incorporated by reference.
Equally preferred according to the invention are the HMG-CoA reductase inhibitors mentioned in the publication Bioorganic & Medicinal Chemistry, Vol. 5, No. 2,
pages 437-444 (1997), the disclosure of which is hereby incorporated in its entirety by reference.
A further review of HMG-CoA reductase inhibitors is present in Pharmazie in un- serer Zeit, Vol. 28, No. 3, pages 147-1152 (1999).
The aforementioned bile acid absorption inhibitors (bile acid sequestrants) which are preferred according to the invention are cholestyramine (commercially availlable under the name Qestran® from Bristol-Myers Squibb) and colestipol (commercially ~ available under the name Colestid® from Pharmacia & Upjohn) (see also Exp. Opin.
Invest. Drugs (1998), 7(5), pages 715 — 727).
The aforementioned fibric acid derivatives which are preferred according to the invention are ciprofibrate (commercially available under the name Modalim® from
Sanofi Winthrop), fenofibrate (commercially available under the name Lipantil® from Fournier), gemfibrozil (commercially available under the name Lopid® from
Parke-Davis), bezafibrate and clofibrate (see also Exp. Opin. Invest. Drugs (1998), 7(5), pages 715 — 727).
Of the aforementioned nicotinic acid analogs, preference is given according to the invention to acipimox (commercially available under the name Olbetam® from
Pharmacia & Upjohn) (see also Exp. Opin. Invest. Drugs (1998), 7(5), pages 715 — 727).
Of the aforementioned w3-fatty acids, preference is given according to the invention to maxepa (marketed by Seven Seas) (in this connection, see also Exp. Opin. Invest.
Drugs (1998), 7(5), pages 715 — 727).
According to the present invention, the direct soluble guanylate cyclase stimulator can preferably be selected from the compounds described in the publication WO
98/16223, WO 98/16507, WO 98/23619, WO 00/06567, WO 00/06568, incorporated by reference.
It is particularly preferred to use a direct soluble guanylate cyclase stimulator of the following formula (I):
R! R® ha h{ Rr? 5
A in which
R' 1s a saturated, partly unsaturated or aromatic 5- or 6-membered heterocycle having up to 3 heteroatoms from the series S, N and/or O, which may be bonded via a nitrogen atom and which is optionally substituted up to 3 times, identically or differently, by - amino, azido, formyl, mercaptyl, carboxyl, hydroxyl, straight-chain or branched and optionally halogen-, acyloxy-, arylthio- or heteroarylthio-substituted acyl, alkoxy, alkylthio or alkoxycarbonyl each having up to 6 carbon atoms, nitro, cyano, halogen, Cs.jo-aryl which is optionally substituted by straight-chain or branched alkyl having up to 4 carbon atoms, or NO, NHCO-C,_¢-alkyl, N(CO-C,- alkyl),, NHSO,-C,¢-alkyl; - a radical of the formula R'NCOR" which is bonded via the nitrogen atom to the remainder of the molecule, where
R' and R" together with the amide group to which they are bonded form a five- to seven-membered heterocycle which may be saturated or partly unsaturated,
may optionally contain a further heteroatom from the group of N, O, S, and may have one to five further substituents from the group of oxo, C,-alkyl, hydroxyl, hydroxy-Ci.s-alkyl, halogen, or may be fused to a Cq.¢-aryl ring or to a Cig-cycloalkyl ning in which two carbon atoms are optionally linked together via an oxygen atom; - a radical from the group consisting of -OS0,-C, ¢-alkyl, -OS0;-Cj.s- cycloalkyl, -OSO,-phenyl, where the phenyl ring may optionally be substituted; - a radical of the formula -O-CX-NR"R", where
X 1sOorS;
R" and RY may be identical or different from one another and is a radical from the group consisting of H, optionally substituted C,.¢-alkyl, optionally substituted
Ci.¢-alkoxy-C, ¢-alkyl, optionally substituted hydroxy-C;.¢-alkyl, optionally substituted C,.¢-alkenyl, optionally substituted C;.¢-alkylcarbonyloxy-C,.- alkyl, optionally substituted hydroxycarbonyl-C,.¢-alkyl, phenyl which is optionally substituted by a C,¢-alkyl radical, or a saturated five- to seven- membered heterocycle which is optionally linked via a C;¢-alkyl radical to the nitrogen atom, or optionally substituted Cs.s-cycloalkyl, where R? and R* cannot both be H ; or
R"™ and R" together with the nitrogen atom to which they are bonded form a five- to seven-membered saturated heterocycle which may optionally contain a further heteroatom from the group of N, O, S and/or optionally be substituted or fused to a phenyl ring; - a radical of the formula NRYSO,RY! in which
RY and RY! together with the heteroatoms to which they are bonded form a five- to seven-membered heterocycle which may be saturated or partially unsaturated, may optionally comprise one or more further heteroatoms from the group of
N, O, S, and may optionally be substituted; - straight-chain or branched alkenyl or alkynyl having up to 10 carbon atoms or straight-chain or branched alkyl having up to 20 carbon atoms, which may itself optionally be substituted by hydroxyl, amino, azido, carboxyl, straight-chain or branched acyl, alkoxy, alkoxycarbonyl or acylamino having up to 5 carbon atoms, aryl having 6 to 10 carbon atoms, a 5- to 6-membered aromatic heterocycle having up to 3 heteroatoms from the series S, N and/or O, halogen, cyano, dialkylamino having up to 6 carbon atoms, alkylamino having up to 6 carbon atoms and/or cycloalkyl having 3 to 8 carbon atoms or by a radical of the formula -OR" in which R* is straight-chain or branched acyl having up to 5 carbon atoms, - saturated or partially unsaturated C;-Cg-cycloalkyl which may optionally be substituted one or more times by amino, azido, formyl, mercaptyl, carboxyl, hydroxyl, morpholino, piperidino, pyrrolidino, sulfonamino, straight-chain, cyclic or branched acyl, acylamino, alkoxy, benzyloxy, alkylamino, dialkylamino, alkylsulfonyl, alkyl- sulfonamino, alkylthio, alkoxycarbonyl each having up to 6 carbon atoms, nitro, cyano, halogen, phenyl and/or is optionally substituted by straight-chain or branched or cyclic alkyl having up to 6 carbon atoms which may in turn be substituted by amino, mercaptyl, carboxyl, hydroxyl, morpholino, piperidino, pyrrolidino, straight-chain, cyclic or branched acyl, acylamino, alkoxy, alkylamino, dialkylamino, alkylsulfonyl, alkylthio, phenyl, alkylsulfonamino, alkoxycarbonyl each having up to 6 carbon atoms, nitro, cyano, halogen, - a 3-8-membered ring which may be saturated, unsaturated or partially unsaturated, comprises 1-4 heteroatoms from the series N, O, S, SO,
SO, and which may also be linked via N, with particular preference for imidazolyl, imidazolinyl, imidazolidinyl, morpholino, piperidine, piperazine, pyrrolidine, triazolyl, pyrrole, pyridine, thiomorpholino, s- oxothiomorpholino and S,S-dioxothiomorpholino or a radical of the formula
NT NN" n or
O 0) )n in whichnis 1 or 2; and which is optionally substituted one or more times by a 5- or 6-membered ring which comprises two oxygen atoms as ring members and forms with the 3-8- membered ring a bicyclic unit or a spiro unit, and/or hydroxyl, cyano, straight-chain or branched alkyl, acyl or alkoxycarbonyl each having up to 6 carbon atoms, where alkyl, acyl and alkoxycarbonyl may be substituted by hydroxyl, amino, halogen, carboxyl, straight-chain or branched acyl, alkoxy, alkoxycarbonyl or acylamino each having up to 5 carbon atoms, - a radical of the formula
O(CH,),
OT ( MN
OCH3(CH,), O(CH,), NS ors “SNH
OH 67
N s or -S(O),-NR R \—-0 in which a, b and b' are identical or different and are a number 0, 1, 2 or 3,
RS is hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,
C 1s a number 1 or 2, and
RO and R7 are identical or different and are hydrogen or straight-chain or branched alkyl having up to 10 carbon atoms, which is optionally substituted by cycloalkyl having 3 to 8 carbon atoms or by aryl having 6 to 10 carbon atoms, which may in turn be substituted by halogen, or aryl having 6 to 10 carbon atoms which is optionally substituted by halogen, or cycloalkyl having 3 to 7 carbon atoms, or R® and R7 together with the nitrogen atom form a 5-to 7-membered saturated heterocycle which may optionally comprise a further oxygen atom or a -NRS& radical, in which
R8 is hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or a radical of the formula
Jeu;
Cc 0)
H; or benzyl or phenyl, where the ring systems are optionally substituted by halogen, - radicals of the formulae -SO;H or -S(O)qR® in which d 1s a number 1 or 2,
R’ is straight-chain or branched alkyl having 1 to 10 carbon atoms, cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or a saturated or unsaturated 5- to 6-membered heterocycle having up to 3 heteroatoms from the series S, N and/or O, where the ring systems may optionally be substituted by halogen or by straight-chain or branched alkyl or alkoxy each having up to 4 carbon atoms, - a radical of the formula PO(OR'®)(OR'") in which
R'" and R'' are identical or different and are hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or benzyl, - oxycycloalkyl having 3 to 8 ring members or radicals of the formulae -CON=C(NH,),, -C=NH(NH,), -NH-C(=NH)NH, or (CO).NR"’R", in which e 1s anumber O or 1, - R'? and R" are identical or different and are hydrogen, straight-chain or branched alkyl having up to 14 carbon atoms or cycloalkyl having 3 to 14 carbon atoms, aryl having 6 to 10 carbon atoms or a saturated or unsaturated 3-to 10- membered ring having up to 5 heteroatoms from the series N, O, S, where said radicals may optionally be substituted by aryl having 6 to 10 carbon atoms, heterocyclyl, cycloalkyl having 3 to 7 carbon atoms, hydroxyl, amino or straight-chain or branched alkoxy, acyl or alkoxycarbonyl each having up to 6 carbon atoms, and in the case where eis 1,
R'? and R" may also form, with inclusion of the nitrogen atom to which they are bonded, a 5- or 6-membered ring having up to 3 heteroatoms from the series
N, O, S, which may optionally be substituted up to 3 times by hydroxyl, alkoxy or alkyl each having up to 8 carbon atoms, and in the case where e 1s 0,
R'? and R" may also be straight-chain, branched or cyclic acyl having up to 14 carbon atoms, hydroxyalkyl, straight-chain or branched alkoxycarbonyl or acyloxyalkyl each having up to 6 carbon atoms or a radical of the formula -SO,R" in which
R14 is straight-chain or branched alkyl having up to 4 carbon atoms, with the proviso that in the case where e is 0, R'? and R" are not both hydrogen, - a purine residue which may optionally be substituted up to three times by halogen, azido, cyano, hydroxyl, amino, monoalkylamino having up to 5 carbon atoms, dialkylamino having in each case up to 5 carbon atoms, alkyl having up to 5 carbon atoms and/or alkoxy having up to 5 carbon atoms,
R?and R® form, with inclusion of the double bond, a 6-membered saturated or aromatic heterocycle having up to 3 heteroatoms from the series N, S and/or
O or a phenyl ring which are optionally substituted up to 3 times identically or differently by formyl, mercaptyl, carboxyl, hydroxyl, amino, straight-chain or branched acyl, alkylthio, alkoxy, alkoxycarbonyl having in each case up to 6 carbon atoms, nitro, cyano, azido, halogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms which may in turn be substituted by hydroxyl, amino, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 5 carbon atoms,
A is phenyl or a 5- to 6-membered aromatic or saturated heterocycle having up to 3 heteroatoms from the series S, N and/oder O, each of which is optionally substituted up to 3 times identically or differently by mercaptyl, hydroxyl, formyl, carboxyl, straight-chain or branched acyl, alkylthio, alkyloxyacyl, alkoxy or alkoxycarbonyl each having up to 6 carbon atoms, nitro, cyano, trifluoromethyl, azido, halogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms which may in turn be substituted by hydroxyl, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 5 carbon atoms, and/or are substituted by a group of the formula -(CO)~-NR"R'® in which d isanumberOor 1,
R'® and R'® are identical or different and are hydrogen, phenyl, benzyl or straight- chain or branched alkyl or acyl each having up to 5 carbon atoms, and the isomeric forms and salts thereof and the N-oxides thereof.
It is particularly preferred according to the invention to use a direct soluble guanylate cyclase stimulator of the formula (Ia)
R! NH, a N \ /
Ss
Ns
N N
0 -
F in which
R is a saturated or unsaturated, optionally substituted Cs_g-cycloalkyl, or is a saturated, unsaturated or partially unsaturated 3-8-membered heterocycle which may comprise 1-4 heteroatoms from the series N, O, S, SO, SO; and optionally be substituted, or is a radical of the formula R"'NCOR™ which is bonded via the nitrogen atom to the remainder of the molecule, where Ri and R™ together with the amide group to which they are bonded form a five- or six-membered saturated heterocycle which may optionally comprise a further oxygen atom and may have one to five further substituents from the group of oxo, Ci 4-alkyl, or may be fused with a phenyl ning; or is 4-pyridinyl or 3-pyridinyl;
R" is H, halogen or NH,, or
R' and R" together form a radical of the formula
SNH ov
NZ
\_—-0
It is preferred according to the present invention to use compounds of the formula (Ia) in which
R' is an optionally substituted cyclopropyl, cyclobutyl, cyclopentenyl, cyclopentyl, cyclohexyl, 1-hydroxycyclopropyl or 1-(fluoro- methyl)cyclopropyl radical or is optionally substituted morpholino, piperidine, piperazine, pyrrolidine, 4-pyridinyl or 3-pyridinyl, triazolyl or thiomorpholino;
R" 1s H, halogen or NH, or
R' and R" together form a radical of the formula “SNH ov
NZ
\—-0
It is preferred according to the present invention to use a compound of the formula (Ia) in which
R' is a cyclopropyl radical, a 1-hydroxyl-cyclopropyl radical, morpholino, 4- pyridinyl or 3-pyridinyl,
RY is H or NH;, or
R' and R" together form a radical of the formula “SNH oH
NZ
\—0
The compounds of the invention of the general formula (I) may also exist in the form of their salts. In general, mention may be made here of salts with organic or inorganic bases or acids.
Physiologically acceptable salts are preferred for the purposes of the present invention. Physiologically acceptable salts of the compounds of the invention may be salts of the substances of the invention with mineral acids, carboxylic acids or sulfonic acids. Particularly preferred examples are salts with hydrochlonc acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
Physiologically acceptable salts may be metal or ammonium salts of the compounds of the invention having a free carboxyl group. Particularly preferred examples are sodium, potassium, magnesium or calcium salts, and ammonium salts derived from ammonia or organic amines such as, for example, ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine or ethylenediamine.
The compounds of the invention may exist in stereoisomeric forms which either are related as image and mirror image (enantiomers) or which are not related as image and mirror image (diastereomers). The invention relates both to the enantiomers or diastereomers and to respective mixtures thereof. The racemic forms can, just like the diastereomers, be separated in a known manner, for example by chromatographic separation, into the stereoisomerically pure constituents. Double bonds present in the compounds of the invention may be in the cis or trans configuration (Z or E form).
In addition, certain compounds may exist in tautomeric forms. This is known to the skilled worker, and such compounds are likewise encompassed by the invention.
The compounds of the invention may additionally occur in the form of their hydrates, with the number of water molecules bound to the molecule depending on the particular compound of the invention.
Unless indicated otherwise, the substituents have for the purposes of the present invention in general the following meanings:
Alkyl is generally a straight-chain or branched hydrocarbon radical having 1 to 20 carbon atoms. Examples which may be mentioned are methyl, ethyl, propyl, 1sopropyl, butyl, isobutyl, pentyl, isopentyl, hexyl, isohexyl, heptyl, isoheptyl, octyl and isooctyl, nonyl, decyl, dodeyl, eicosyl.
Alkenyl is generally a straight-chain or branched hydrocarbon radical having 2 to 20 carbon atoms and one or more, preferably having one or two, double bonds.
Examples which may be mentioned are allyl, propenyl, isopropenyl, butenyl, 1sobutenyl, pentenyl, isopentenyl, hexenyl, isohexenyl, heptenyl, isoheptenyl, octenyl, 1sooctenyl.
Alkynyl is generally a straight-chain or branched hydrocarbon radical having 2 to 20 carbon atoms and one or more, preferably having one or two, triple bonds. Examples which may be named are ethynyl, 2-butynyl, 2-pentinyl and 2-hexynyl.
Acyl 1s generally straight-chain or branched lower alkyl having 1 to 9 carbon atoms which is linked via a carbonyl group. Examples which may be mentioned are: acetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl and isobutylcarbonyl. © Alkoxy is generally a straight-chain or branched hydrocarbon radical having 1 to 14 carbon atoms which is linked via an oxygen atom. Examples which may be mentioned are methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy isopentoxy, hexoxy, isohexoxy, heptoxy, isoheptoxy, octoxy or isooctoxy. The terms "alkoxy" and "alkyloxy" are used synonymously.
Alkoxvyalkyl is generally an alkyl radical having up to 8 carbon atoms which is substituted by an alkoxy radical having up to 8 carbon atoms.
Alkoxycarbonyl can be represented for example by the formula (TOA ©
Alkyl in this case is generally a straight-chain or branched hydrocarbon radical having 1 to 13 carbon atoms. The following alkoxycarbonyl radicals may be mentioned for example: methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, iso- propoxycarbonyl, butoxycarbonyl or isobutoxycarbonyl.
Cycloalkyl is generally a cyclic hydrocarbon radical having 3 to 8 carbon atoms.
Cyclopropyl, cyclopentyl and cyclohexyl are preferred. Examples which may be mentioned are cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
Cycloalkoxy is for the purposes of the invention an alkoxy radical whose hydrocarbon radical is a cycloalkyl radical. The cycloalkyl radical generally has up to 8 carbon atoms. Examples which may be mentioned are: cyclopropyloxy and cyclohexyloxy. The terms '"cycloalkoxy" and ‘"cycloalkyloxy" are used synonymously.
Aryl is generally an aromatic radical having 6 to 10 carbon atoms. Phenyl and naphthyl are preferred aryl radicals.
Halogen is for the purposes of the invention fluorine, chlorine, bromine and iodine.
Heterocycle is for the purposes of the invention generally a saturated, unsaturated or aromatic 3- to 10-membered, for example 5- or 6-membered, heterocycle which may comprise up to 3 heteroatoms from the series S, N and/or O, and which in the case of a nitrogen atom may also be bonded via the latter. Examples which may be mentioned are: oxadiazolyl, thiadiazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, furyl, pyrrolyl, pyrrolidinyl, piperazinyl, tetrahydropyranyl, tetrahydrofuranyl, 1,2,3 triazolyl, thiazolyl, oxazolyl, imidazolyl, morpholinyl or piperidyl. Thiazolyl, furyl, oxazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl and tetrahydropyranyl are preferred. The term "heteroaryl" (or "hetaryl") stands for an aromatic heterocyclic radical.
Apart from the two active ingredient components A and B mentioned above, the combination product of the invention may also comprise any other active ingredients as long as they do not conflict with the area of indications and do not impair the effect of the direct soluble guanylate cyclase stimulator and of the lipid-lowering agent. In particular, it is possible to add to the composition of the invention organic nitrates or NO donors — that is to say compounds which stimulate the synthesis of cGMP - or compounds which inhibit the breakdown of cyclic guanosine monophosphate (cGMP).
Organic nitrates and NO donors for the purposes of the invention are generally substances which display their therapeutic effect via release of NO or NO species.
Sodium nitroprusside, nitroglycerine, isosorbide dinitrate, isosorbide mononitrate, molsidomine and SIN-1 are preferred.
The invention additionally encompasses combination with compounds which inhibit the breakdown of cyclic guanosine monophosphate (cGMP). These are, in particular, inhibitors of phosphodiesterases 1, 2‘ and 5; nomenclature of Beavo and Reifsnyder (1990) TiPS 11 pages 150 to 155. These inhibitors potentiate the effect of the compound of the invention and increase the desired pharmacological effect.
These other active ingredients which are preferably present may — just like the active ingredient components A and B — be present either as true mixture together with A and/or B or else be present spatially separate therefrom. Administration thereof can take place in parallel or simultaneously or sequentially in rclation to the active ingredient component(s) A and/or B.
The other active ingredients preferably present in the combination product of the invention include, for example: e other active ingredients improving erectile ability, for example: cGMP PDE inhibitors such as, for example, sildenafil (EP-B-0 463 756), IC 351 (WO 95/19978) or vardenafil (WO 99/24433), a-adrenergic antagonists such as, for example, yohimbin or Vasomax® from Zonagen; or else substances like those mentioned in WO-A-98/52569, the contents of which are hereby included by reference; or prostaglandins E1; or seretonin antagonists; e active ingredients from the cardiovascular area of indications; e active ingredients from the CNS and cerebral areas of indications; e vitamins; e minerals; e trace elements.
All conventional administration forms are suitable in each case for administering the two active ingredient components A and B (and the other active ingredients present where appropriate). Administration preferably takes place orally, perlingually, sublin- gually, nasally, transdermally, buccally, intravenously, rectally, by inhalation or parenterally. Administration preferably takes place orally, sublingually or nasally.
Oral administration is very particularly preferred.
It is additionally possible to administer the two active ingredient components A and
B in different dosage forms if administration is spatially separate or at different times.
The two active ingredient components A and B can be converted — together or spatially separate — in each case in a manner known per se into the conventional formulations such as tablets, coated tablets, pills, granules, aerosols, syrups, emul- sions, suspensions and solutions, using inert, nontoxic, pharmaceutically suitable carriers or solvents. In these cases, the therapeutically active components A and B should each be present in a concentration of about 0.5 to 90% by weight of the complete mixture, i.e. in amounts which suffice to reach the stated dosage range.
The formulations are produced for example by extending the two active ingredient components A and B with solvents and/or carriers, where appropriate using emulsifiers and/or dispersants, it being possible, for example in the case where water is used as diluent, where appropriate to use organic solvents and auxiliary solvents.
The dosages administered on oral administration for human use are from 0.001 to 50 mg/kg, preferably from 0.001 mg/kg to 20 mg/kg, in particular 0.001 to 10 mg/kg, of body weight, particularly preferably 0.001 mg/kg to 5 mg/kg, of the respective active ingredient component A or B, to achieve effective and worthwhile results.
It may nevertheless be necessary where appropriate to depart from the amounts mentioned here, in particular depending on the body weight and the nature of the administration route, or on the individual behavior toward the combination product, on the nature of the formulation and on the time or interval over which administration takes place. Thus, it may be sufficient in some cases to make do with less than the aforementioned minimum amount, while in other cases the upper limit mentioned must be exceeded.
It may be advisable in the case where relatively large amounts are administered for these to be distributed in a plurality of single doses over the day.
Claims (29)
1. A combination product comprising as pharmaceutically active ingredients at least one active ingredient component A and at least one active ingredient component B, characterized in that the active ingredient component A is a direct soluble guanylate cyclase stimulator and the active ingredient component B is a lipid-lowering agent.
2. The combination product as claimed in claim 1 for the treatment of diseases.
3. The combination product as claimed in one of claims 1 or 2, characterized in that the two active ingredient components A and B are administered separately from one another.
4. The combination product as claimed in claim 3, characterized in that the two active ingredient components A and B are administered sequentially
5. The combination product as claimed in any of claims 1 to 4, characterized in that the active ingredient components A and B are present as functional unit.
6. The combination product as claimed in claim 5, characterized in that the active ingredient components A and B are present as one of a mixture, a mix and a blend.
7. The combination product as claimed in any of claims 1 to 6, characterized in that active ingredient components A and B are present (spatially) separate from one another.
8. The combination product as claimed in claim 7, characterized in that the active ingredient components A and B are present as a kit-of-parts. AMENDED SHHET
9. The combination product as claimed in any of claims 1 to 8, characterized in that the lipid-lowering agent (active ingredient component B) is selected from the group of (a) HMG-CoA reductase inhibitors; (b) squalene synthase inhibitors; (c) bile acid absorption inhibitors (,,bile acid sequestrants*); (d) fibric acid and its derivatives; (e) nicotinic acid and its analogs; (f) w3-fatty acids.
The combination product as claimed in claim 9, characterized in that the lipid-lowering agent (active ingredient component B) is a HMG-CoA reductase inhibitor. 10
11. The combination product as claimed in claim 10, characterized in that the lipid-lowering agent (active ingredient component B) is selected from the group of statins.
12. The combination product as claimed in claim 11, characterized in that the lipid-lowering agent (active ingredient component B) is from the group of atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, pitavastatin, simvastatin and rosuvastatin, and the respective salts, hydrates, alcoholates, esters and tautomers thereof.
13. The combination product as claimed in claim 12, characterized in that the lipid-lowering agent (active ingredient component B) is atorvastatin or its salt, hydrate, alcoholate, ester and tautomer.
14. The combination product as claimed in claim 12, characterized in that the lipid-lowering agent (active ingredient component B) is cerivastatin or its salt, hydrate, alcoholate, ester and tautomer.
15. The combination product as claimed in any of claims 1 to 14, characterized in that the direct soluble guanylate cyclase stimulator (active ingredient component A) is selected from compounds of the following formula (I): AMENDED SHHET
- 26a - Rl R’ Ti AN Rr? L M A in which
R' is a saturated, partly unsaturated or aromatic 5- or 6-membered heterocycle having up to 3 heteroatoms from the series S, N and/or O, which may be bonded via a nitrogen atom and which is optionally substituted up to 3 times, identically or differently, by - amino, azido, formyl, mercaptyl, carboxyl, hydroxyl, straight-chain or branched and optionally halogen-, acyloxy-, arylthio- or heteroarylthio-substituted acyl, alkoxy, alkylthio or alkoxycarbonyl
AMENDED SHHET each having up to 6 carbon atoms, nitro, cyano, halogen, Ce.1o-aryl which is optionally substituted by straight-chain or branched alkyl having up to 4 carbon atoms, or NO, NHCO-C,s-alkyl, N(CO-C,¢- alkyl), NHSO,-C, ¢-alkyl; - a radical of the formula R'NCOR" which is bonded via the nitrogen atom to the remainder of the molecule, where
R' and R" together with the amide group to which they are bonded form a five- to seven-membered heterocycle which may be saturated or partly unsaturated, may optionally contain a further heteroatom from the group of N, O, S, and may have one to five further substituents from the group of oxo, C;.¢-alkyl, hydroxyl, hydroxy-C, ¢-alkyl, halogen, or may be fused to a Cg.jp-aryl ring or to a C;_g-cycloalkyl ring in which two carbon atoms are optionally linked together via an oxygen atom;
- a radical from the group consisting of -OS0O,-C;¢-alkyl, -OS0,-C;s- cycloalkyl, -OSO,-phenyl, where the phenyl ring may optionally be substituted;
- a radical of the formula -O-CX-NR"R", where
X 1sOorS;
R" and RY may be identical or different from one another and is a radical from the group consisting of H, optionally substituted C;-alkyl, optionally substituted C;¢-alkoxy-C,¢-alkyl, optionally substituted hydroxy-C, ¢-alkyl, optionally substituted C,.¢-alkenyl, optionally substituted C;¢-alkylcarbonyloxy-C,¢-alkyl, optionally substituted hydroxycarbonyl-C, ¢-alkyl, phenyl which is optionally substituted by a Ci¢-alkyl radical, or a saturated five- to seven-membered heterocycle which is optionally linked via a C,¢-alkyl radical to the nitrogen atom, or optionally substituted Cs g-cycloalkyl, where R? and R* cannot both be H ;
or R™ and RY together with the nitrogen atom to which they are bonded form a five- to seven-membered saturated heterocycle which may optionally contain a further heteroatom from the group of N, O, S and/or optionally be substituted or fused to a phenyl ring; - a radical of the formula NRYSO,R"' in which R” and RY together with the heteroatoms to which they are bonded form a five- to seven-membered heterocycle which may be saturated or partially unsaturated, may optionally comprise one or more further heteroatoms from the group of N, O, S, and may optionally be substituted;
- straight-chain or branched alkenyl or alkynyl having up to 10 carbon atoms or straight-chain or branched alkyl having up to 20 carbon atoms, which may itself optionally be substituted by hydroxyl, amino, azido, carboxyl, straight-chain or branched acyl, alkoxy, alkoxycarbonyl or acylamino having up to 5 carbon atoms, aryl having 6 to 10 carbon atoms, a 5- to 6-membered aromatic heterocycle having up to 3 heteroatoms from the series S, N and/or O, halogen, cyano, dialkylamino having up to 6 carbon atoms, alkylamino having up to 6 carbon atoms and/or cycloalkyl having 3 to 8 carbon atoms or by a radical of the formula -OR* in which R* is straight-chain or branched acyl having up to 5 carbon atoms,
- saturated or partially unsaturated C;-Cg-cycloalkyl which may optionally be substituted one or more times by amino, azido, formyl, mercaptyl, carboxyl, hydroxyl, morpholino, piperidino, pyrrolidino, sulfonamino, straight-chain, cyclic or branched acyl, acylamino, alkoxy, benzyloxy, alkylamino, dialkylamino, alkylsulfonyl, alkyl-
sulfonamino, alkylthio, alkoxycarbonyl each having up to 6 carbon atoms, nitro, cyano, halogen, phenyl and/or is optionally substituted by straight-chain or branched or cyclic alkyl having up to 6 carbon atoms which may in turn be substituted by amino, mercaptyl, carboxyl, hydroxyl, morpholino, piperidino, pyrrolidino, straight-chain, cyclic or branched acyl, acylamino, alkoxy, alkylamino, dialkylamino, alkylsulfonyl, alkylthio, phenyl, alkylsulfonamino, alkoxycarbonyl each having up to 6 carbon atoms, nitro, cyano, halogen, - a 3-8-membered ring which may be saturated, unsaturated or partially unsaturated, comprises 1-4 heteroatoms from the series N, O, S, SO, SO, and which may also be linked via N, with particular preference for imidazolyl, imidazolinyl, imidazolidinyl, morpholino, piperidine, piperazine, pyrrolidine, triazolyl, pyrrole, pyridine, thiomorpholino, s- oxothiomorpholino and S,S-dioxothiomorpholino or a radical of the formula NT N= n or ) in whichnis 1 or 2; and which is optionally substituted one or more times by a 5- or 6-membered ring which comprises two oxygen atoms as ring members and forms with the 3-8-membered ring a bicyclic unit or a spiro unit, and/or hydroxyl, cyano, straight-chain or branched alkyl, acyl or alkoxycarbonyl each having up to 6 carbon atoms, where alkyl, acyl and alkoxycarbonyl may be substituted by hydroxyl, amino, halogen, carboxyl, straight-chain or branched acyl, alkoxy, alkoxycarbonyl or acylamino each having up to 5 carbon atoms, - a radical of the formula
O(CH,), a — Co MN OCH3z(CH,), O(CH,), ANE on™ =. NEA or -5(0)-NR'R \—"0 in which a, b and b' are identical or different and are a number 0, 1, 2 or 3,
RS is hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms, C 1s a number 1 or 2, and
RO and R7 are identical or different and are hydrogen or straight-chain or branched alkyl having up to 10 carbon atoms, which is optionally substituted by cycloalkyl having 3 to 8 carbon atoms or by aryl having 6 to 10 carbon atoms, which may in turn be substituted by halogen, or aryl having 6 to 10 carbon atoms which is optionally substituted by halogen, or cycloalkyl having 3 to 7 carbon atoms, or R® and R7 together with the nitrogen atom form a 5-to 7-membered saturated heterocycle which may optionally comprise a further oxygen atom or a -NR8 radical, in which
RS is hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or a radical of the formula
Jon; -CH; 0 or benzyl or phenyl, where the ring systems are optionally substituted by halogen, - radicals of the formulae -SO;H or -S(O)qR’ in which d 1s a number 1 or 2, R’ 1s straight-chain or branched alkyl having 1 to 10 carbon atoms, cyclo-
alkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or a saturated or unsaturated S5- to 6-membered heterocycle having up to 3 heteroatoms from the series S, N and/or O, where the ring systems may optionally be substituted by halogen or by straight-chain or branched alkyl or alkoxy each having up to 4 carbon atoms,
- a radical of the formula PO(OR'®)(OR") in which
R'® and R'! are identical or different and are hydrogen, straight-chain or branched alkyl having up to 8 carbon atoms or cycloalkyl having 3 to 8 carbon atoms, aryl having 6 to 10 carbon atoms or benzyl,
- oxycycloalkyl having 3 to 8 ring members or radicals of the formulae -CON=C(NH,),, -C=NH(NH,), -NH-C(=NH)NH, or (CO).NR'’R", in which e 1s anumber OQ or 1,
R'? and R" are identical or different and are hydrogen, straight-chain or branched alkyl having up to 14 carbon atoms or cycloalkyl having 3 to 14 carbon atoms, aryl having 6 to 10 carbon atoms or a saturated or unsaturated 3-to 10-membered ring having up to 5 heteroatoms from the series N, O, S, where said radicals may optionally be substituted by aryl having 6 to 10 carbon atoms, heterocyclyl, cycloalkyl having 3 to 7 carbon atoms, hydroxyl, amino or straight-chain or branched alkoxy, acyl or alkoxycarbonyl each having up to 6 carbon atoms,
and in the case where eis 1, R'? and R"® may also form, with inclusion of the nitrogen atom to which they are bonded, a 5- or 6-membered ning having up to 3 heteroatoms from
- the series N, O, S, which may optionally be substituted up to 3 times by hydroxyl, alkoxy or alkyl each having up to 8 carbon atoms, and in the case where ¢ is 0,
R'? and R"® may also be straight-chain, branched or cyclic acyl having up to 14 carbon atoms, hydroxyalkyl, straight-chain or branched alkoxycarbonyl or acyloxyalkyl each having up to 6 carbon atoms or a radical of the formula -SO,R'* in which
R14 is straight-chain or branched alkyl having up to 4 carbon atoms, with the proviso that in the case where e 1s 0, R'? and R" are not both hydrogen,
- a purine residue which may optionally be substituted up to three times by halogen, azido, cyano, hydroxyl, amino, monoalkylamino having up to 5 carbon atoms, dialkylamino having in each case up to 5 carbon atoms, alkyl having up to 5 carbon atoms and/or alkoxy having up to 5 carbon atoms,
R? and R’ form, with inclusion of the double bond, a 6-membered saturated or aromatic heterocycle having up to 3 heteroatoms from the series N, S and/or O or a phenyl ring which are optionally substituted up to 3 times identically or differently by formyl, mercaptyl, carboxyl,
hydroxyl, amino, straight-chain or branched acyl, alkylthio, alkoxy, alkoxycarbonyl having in each case up to 6 carbon atoms, nitro, cyano, azido, halogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms which may in turn be substituted by hydroxyl, amino, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 5 carbon atoms,
A is phenyl or a 5- to 6-membered aromatic or saturated heterocycle having up to 3 heteroatoms from the series S, N and/oder O, each of which is optionally substituted up to 3 times identically or differently by mercaptyl, hydroxyl, formyl, carboxyl, straight-chain or branched acyl, alkylthio, alkyloxyacyl, alkoxy or alkoxycarbonyl each having up to 6 carbon atoms, nitro, cyano, trifluoromethyl, azido, halogen, phenyl or straight-chain or branched alkyl having up to 6 carbon atoms which may in turn be substituted by hydroxyl, carboxyl, straight-chain or branched acyl, alkoxy or alkoxycarbonyl each having up to 5 carbon atoms, and/or are substituted by a group of the formula -(CO)¢ NR"R'® in which d 1sanumber Oor 1,
R'® and R'® are identical or different and are hydrogen, phenyl, benzyl or straight-chain or branched alkyl or acyl each having up to 5 carbon atoms,
and the isomeric forms and salts thereof and the N-oxides thereof.
16. The combination product as claimed in claim 15, characterized in that the direct soluble guanylate cyclase stimulator is selected from compounds of the formula (Ia)
Re \ N \ / SS N \ % “N N 0 - F in which R’ is a saturated or unsaturated, optionally substituted Cs.g-cycloalkyl, or is a saturated, unsaturated or partially unsaturated 3-8-membered heterocycle which may comprise 1-4 heteroatoms from the series N, 0, S, SO, SO; and optionally be substituted, or is a radical of the formula RNCOR™ which is bonded via the nitrogen atom to the remainder of the molecule, where Ri and R™ together with the amide group to which they are bonded form a five- or six-membered saturated heterocycle which may optionally comprise a further oxygen atom and may have one to five further substituents from the group of oxo, C;4-alkyl, or may be fused with a phenyl ring; or is 4-pyridinyl or 3-pyridinyl; AMENDED SHHET
Ri is H, halogen or NH, or R' and R" together form a radical of the formula ~ NH 21 T=
17. The combination product as claimed in claim 16, characterized in that R is an optionally substituted cyclopropyl, cyclobutyl, cyclopentenyl, cyclopentyl, cyclohexyl, 1-hydroxycyclopropyl or 1-(fluoro- methyl)cyclopropyl radical or is optionally substituted morpholino, piperidine, piperazine, pyrrolidine, 4-pyridinyl or 3-pyridinyl, triazolyl or thiomorpholino; R' is H, halogen or NH, or R' and R" together form a radical of the formula ~ NH 2X AN
18. The combination product as claimed in claim 16, characterized in that R’ is a cyclopropyl radical, a 1-hydroxyl-cyclopropyl radical, morpholino, 4-pyridinyl or 3-pyridinyl, Rf 1s H or NH;, or AMENDED SHHET
R' and R" together form a radical of the formula SNH 2 TL,
19. The use of lipid-lowering agents for increasing efficacy of direct soluble guanylate cyclase stimulators.
20. A process for producing compositions as claimed in any of claims 1 to 18, characterized in that at least one lipid-lowering agent and at least one direct soluble guanylate cyclase stimulator are converted, where appropriate with conventional excipients and additives, into a suitable administration form.
21. The use of compositions as claimed in any of claims 1 to 18 in the production of medicaments for the treatment of cardiovascular disorders.
22. The use of compositions as claimed in any of claims 1 to 18 in the production of medicaments for the treatment of hypertension.
23. The use of compositions as claimed in any of claims 1 to 18 in the production of medicaments for the treatment of thromboembolic disorders and ischaemias.
24. The use of compositions as claimed in any of claims 1 to 18 in the production of medicaments for the treatment of sexual dysfunction.
25. The use of compositions as claimed in any of claims 1 to 18 in the production of medicaments for the treatment of arteriosclerosis. AMENDED SHHET
26. The use of compositions as claimed in any of claims 1 to 18 in the production of medicaments for the treatment of osteoporosis.
27. The use of compositions as claimed in any of claims 1 to 18 in the production of medicaments having an antiinflammatory effect.
28. The use of compositions as claimed in any of claims 1 to 18 in the production of medicaments for the treatment of disorders of the central nervous system.
29. The use as claimed in any of claims 16 to 28, where the compositions as claimed in any of claims 1 to 18 are employed in combination with organic nitrates or NO donors or in combination with compounds which inhibit the breakdown of cyclic guanosine monophosphate (cGMP). AMENDED SHHET
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE101404212 | 2001-08-17 | ||
PCT/EP2002/008701 WO2003015770A1 (en) | 2001-08-17 | 2002-08-05 | Novel combination |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200401181B true ZA200401181B (en) | 2005-04-26 |
Family
ID=58053182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2004/01181A ZA200401181B (en) | 2001-08-17 | 2004-02-13 | Novel combination |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200401181B (en) |
-
2004
- 2004-02-13 ZA ZA2004/01181A patent/ZA200401181B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070225299A1 (en) | Novel Combination Containing a Stimulator of Soluble Guanylate Cyclase and a Lipid-Lowering Substance | |
KR101433394B1 (en) | Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
JP5876435B2 (en) | Use of HDAC inhibitors for the treatment of myeloma | |
JPH08503451A (en) | Use of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors as a modality for cancer treatment | |
US20220362241A1 (en) | Novel methods | |
US20040186163A1 (en) | Novel combination | |
ZA200401181B (en) | Novel combination | |
US20050182036A1 (en) | Medicinal composition containing an HMG-CoA reductase inhibitor | |
CA2492781A1 (en) | Medicinal composition for mitigating blood lipid or lowering blood homocystein | |
JP2003503342A (en) | Combinations of MTP inhibitors and HMG-CoA reductase inhibitors and their use in medicine | |
CA2480275A1 (en) | Statin therapy for enhancing cognitive maintenance | |
US20080070938A1 (en) | Medicinal composition for mitigating blood lipid or lowering blood homocysteine | |
KR20140009222A (en) | Dexamethasone combination therapy | |
JP4607436B2 (en) | Pharmaceutical composition containing an HMG-CoA reductase inhibitor | |
TW200404533A (en) | Blood lipid ameliorant compositions | |
CA2494801A1 (en) | Medicinal composition containing hmg-coa reductase inhibitor | |
AU2013203070B2 (en) | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
EP2033646A1 (en) | Prophylactic and/or therapeutic agent for rheumatoid arthritis | |
KR20090035643A (en) | Drug formulation containing fibrate medicament and process for producing the same | |
WO2009104150A1 (en) | Combination comprising bosentan for treating ovarian cancer |